• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

珠穆朗玛峰研究报告3:息肉状脉络膜血管病变的诊断挑战。从珠穆朗玛峰研究中的筛查失败中吸取的教训。

EVEREST study report 3: diagnostic challenges of polypoidal choroidal vasculopathy. Lessons learnt from screening failures in the EVEREST study.

作者信息

Tan Colin S, Ngo Wei Kiong, Lim Louis W, Tan Nikolle W, Lim Tock H

机构信息

Fundus Image Reading Centre, National Healthcare Group Eye Institute, Singapore, Singapore.

National Healthcare Group Eye Institute, Tan Tock Seng Hospital, 11 Jalan Tan Tock Seng, Singapore, 308433, Singapore.

出版信息

Graefes Arch Clin Exp Ophthalmol. 2016 Oct;254(10):1923-1930. doi: 10.1007/s00417-016-3333-y. Epub 2016 May 3.

DOI:10.1007/s00417-016-3333-y
PMID:27142805
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5045476/
Abstract

PURPOSE

To describe screening failures in the EVEREST study by examining the imaging characteristics that enabled differentiation of polypoidal choroidal vasculopathy (PCV) from cases that were subsequently diagnosed not to be PCV.

METHODS

Post-hoc analysis of 34 patients with PCV reported as screening failures from EVEREST study. Standardised confocal scanning laser indocyanine green angiography (ICGA) images were graded by the Central Reading Centre to confirm PCV diagnosis based on the presence of early focal sub-retinal hyperfluorescence on ICGA and at least one of the following six diagnostic criteria: (1) nodular appearance of polyp(s) on stereoscopic examination, (2) hypofluorescent halo around nodule(s), (3) presence of a branching vascular network, (4) pulsation of polyp(s) on dynamic ICGA, (5) orange sub-retinal nodules on colour fundus photography, or (6) massive sub-macular haemorrhage (≥4 disc areas in size). Additional detailed image grading was performed with stereo-imaging and dynamic early-phase ICGA.

RESULTS

Of the 95 screened PCV cases, 34 were excluded: (1) cases not suitable for recruitment as per the study protocol (n = 14), (2) equivocal lesions on ICGA characterised by small hyperfluorescent dots (n = 9), and (3) cases that were definitely not PCV (non-PCV, n = 11), identified by definitive diagnoses which included one case each of micro-aneurysm, retinal angiomatous proliferation, retino-choroidal anastomosis, small type-2 choroidal neovascularisation, retinal pigment epithelial (RPE) window defect and disciform scar; two cases of lesions where the choroidal vessel changed its course; and three cases of late-onset RPE staining.

CONCLUSIONS

Standardised image grading techniques used in EVEREST study enabled effective differentiation of non-PCV from actual PCV.

摘要

目的

通过检查能够区分息肉样脉络膜血管病变(PCV)与随后诊断为非PCV病例的影像学特征,描述EVEREST研究中的筛查失败情况。

方法

对EVEREST研究中报告为筛查失败的34例PCV患者进行事后分析。标准化共焦扫描激光吲哚菁绿血管造影(ICGA)图像由中央阅读中心分级,以根据ICGA上早期局灶性视网膜下高荧光的存在以及以下六个诊断标准中的至少一项来确认PCV诊断:(1)立体检查时息肉的结节状外观,(2)结节周围的低荧光晕,(3)分支血管网络的存在,(4)动态ICGA上息肉的搏动,(5)彩色眼底照相上橙色视网膜下结节,或(6)巨大黄斑下出血(面积≥4个视盘)。使用立体成像和动态早期ICGA进行额外的详细图像分级。

结果

在95例筛查的PCV病例中,34例被排除:(1)根据研究方案不适合纳入的病例(n = 14),(2)ICGA上表现为小的高荧光点的可疑病变(n = 9),以及(3)明确不是PCV的病例(非PCV,n = 11),通过明确诊断确定,其中包括微动脉瘤、视网膜血管瘤样增生、视网膜脉络膜吻合、小型2型脉络膜新生血管、视网膜色素上皮(RPE)窗缺损和盘状瘢痕各1例;2例脉络膜血管改变走行的病变;以及3例迟发性RPE染色。

结论

EVEREST研究中使用的标准化图像分级技术能够有效区分非PCV与实际PCV。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4bff/5045476/34b6f89b80d1/417_2016_3333_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4bff/5045476/6f573ff104b9/417_2016_3333_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4bff/5045476/8b750a64e783/417_2016_3333_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4bff/5045476/3865be56a076/417_2016_3333_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4bff/5045476/6444e359f748/417_2016_3333_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4bff/5045476/34b6f89b80d1/417_2016_3333_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4bff/5045476/6f573ff104b9/417_2016_3333_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4bff/5045476/8b750a64e783/417_2016_3333_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4bff/5045476/3865be56a076/417_2016_3333_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4bff/5045476/6444e359f748/417_2016_3333_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4bff/5045476/34b6f89b80d1/417_2016_3333_Fig5_HTML.jpg

相似文献

1
EVEREST study report 3: diagnostic challenges of polypoidal choroidal vasculopathy. Lessons learnt from screening failures in the EVEREST study.珠穆朗玛峰研究报告3:息肉状脉络膜血管病变的诊断挑战。从珠穆朗玛峰研究中的筛查失败中吸取的教训。
Graefes Arch Clin Exp Ophthalmol. 2016 Oct;254(10):1923-1930. doi: 10.1007/s00417-016-3333-y. Epub 2016 May 3.
2
IMPROVED SPECIFICITY OF POLYPOIDAL CHOROIDAL VASCULOPATHY DIAGNOSIS USING A MODIFIED EVEREST CRITERIA.使用改良的珠穆朗玛峰标准提高息肉状脉络膜血管病变诊断的特异性
Retina. 2015 Jul;35(7):1375-80. doi: 10.1097/IAE.0000000000000482.
3
EVEREST study report 2: imaging and grading protocol, and baseline characteristics of a randomised controlled trial of polypoidal choroidal vasculopathy.珠穆朗玛峰研究报告2:息肉状脉络膜血管病变随机对照试验的成像与分级方案及基线特征
Br J Ophthalmol. 2015 May;99(5):624-8. doi: 10.1136/bjophthalmol-2014-305674. Epub 2015 Mar 10.
4
EVEREST study report 4: Fluorescein angiography features predictive of polypoidal choroidal vasculopathy.EVEREST 研究报告 4:荧光素血管造影特征预测息肉样脉络膜血管病变。
Clin Exp Ophthalmol. 2019 Jul;47(5):614-620. doi: 10.1111/ceo.13464. Epub 2019 Feb 10.
5
EVEREST Report 5: Clinical Outcomes and Treatment Response of Polypoidal Choroidal Vasculopathy Subtypes in a Multicenter, Randomized Controlled Trial.EVEREST 报告 5:多中心、随机对照试验中息肉样脉络膜血管病变亚型的临床结局和治疗反应。
Invest Ophthalmol Vis Sci. 2018 Feb 1;59(2):889-896. doi: 10.1167/iovs.17-22683.
6
Non-ICGA treatment criteria for Suboptimal Anti-VEGF Response for Polypoidal Choroidal Vasculopathy: APOIS PCV Workgroup Report 2.非 ICGA 治疗标准用于治疗脉络膜息肉样血管病变的抗 VEGF 反应不佳:APOIS PCV 工作组报告 2。
Ophthalmol Retina. 2021 Oct;5(10):945-953. doi: 10.1016/j.oret.2021.04.002. Epub 2021 Apr 16.
7
Appearance of Polypoidal Lesions in Patients With Polypoidal Choroidal Vasculopathy Using Swept-Source Optical Coherence Tomographic Angiography.应用扫频源光学相干断层血管造影术观察息肉样脉络膜血管病变患者的息肉样病变。
JAMA Ophthalmol. 2019 Jun 1;137(6):642-650. doi: 10.1001/jamaophthalmol.2019.0449.
8
Differentiating Exudative Macular Degeneration and Polypoidal Choroidal Vasculopathy Using OCT B-Scan.利用 OCT B 扫描区分渗出性年龄相关性黄斑变性和息肉样脉络膜血管病变。
Ophthalmol Retina. 2021 Oct;5(10):954-961. doi: 10.1016/j.oret.2021.05.009. Epub 2021 May 19.
9
The role of indocyanine green angiography imaging in further differential diagnosis of patients with nAMD who are morphologically poor responders to ranibizumab in a real-life setting.吲哚菁绿血管造影成像在现实环境中对雷珠单抗形态学反应不佳的新生血管性年龄相关性黄斑变性患者进一步鉴别诊断中的作用。
Eye (Lond). 2016 Jul;30(7):958-65. doi: 10.1038/eye.2016.71. Epub 2016 Apr 15.
10
Understanding indocyanine green angiography in polypoidal choroidal vasculopathy: the group experience with digital fundus photography and confocal scanning laser ophthalmoscopy.了解吲哚菁绿血管造影在息肉状脉络膜血管病变中的应用:数字眼底摄影和共焦扫描激光眼科显微镜检查的团队经验
Retina. 2014 Dec;34(12):2397-406. doi: 10.1097/IAE.0000000000000255.

引用本文的文献

1
New Concepts for the Diagnosis of Polypoidal Choroidal Vasculopathy.息肉样脉络膜血管病变诊断的新概念
Diagnostics (Basel). 2023 May 9;13(10):1680. doi: 10.3390/diagnostics13101680.
2
Regulates Subclinical Inflammation and Activates Proangiogenic Response in the Retina and Choroid.调节视网膜和脉络膜的亚临床炎症并激活促血管生成反应。
Int J Mol Sci. 2022 Sep 6;23(18):10206. doi: 10.3390/ijms231810206.
3
Optical coherence tomography in diagnosing polypoidal choroidal vasculopathy. Looking into the future: a systematic review and meta-analysis.

本文引用的文献

1
Submacular hemorrhage in neovascular age-related macular degeneration: A synthesis of the literature.新生血管性年龄相关性黄斑变性的黄斑下出血:文献综述。
Surv Ophthalmol. 2016 Jan-Feb;61(1):18-32. doi: 10.1016/j.survophthal.2015.04.004. Epub 2015 Jul 23.
2
One-Year Results of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy.特发性息肉样脉络膜血管病变玻璃体内注射阿柏西普治疗的一年结果。
Ophthalmology. 2015 Sep;122(9):1866-72. doi: 10.1016/j.ophtha.2015.05.024. Epub 2015 Jun 16.
3
EVEREST study report 2: imaging and grading protocol, and baseline characteristics of a randomised controlled trial of polypoidal choroidal vasculopathy.
光学相干断层扫描在诊断息肉样脉络膜血管病变中的应用。展望未来:一项系统评价与荟萃分析。
Int J Retina Vitreous. 2022 Feb 28;8(1):14. doi: 10.1186/s40942-022-00365-5.
4
Comparison of Polypoidal Choroidal Vasculopathy Lesion Sizes Measured on Multicolor Imaging and Indocyanine Green Angiography.多光谱成像与吲哚菁绿血管造影测量的息肉样脉络膜血管病变病灶大小比较。
Transl Vis Sci Technol. 2021 Feb 5;10(2):35. doi: 10.1167/tvst.10.2.35.
5
The Role of Imaging in Planning Treatment for Central Serous Chorioretinopathy.影像学在中心性浆液性脉络膜视网膜病变治疗规划中的作用
Pharmaceuticals (Basel). 2021 Jan 29;14(2):105. doi: 10.3390/ph14020105.
6
Comparison of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: The EVEREST II Randomized Clinical Trial.抗 VEGF 治疗伴或不伴光动力疗法治疗息肉状脉络膜血管病变的比较: EVEREST II 随机临床试验。
JAMA Ophthalmol. 2020 Sep 1;138(9):935-942. doi: 10.1001/jamaophthalmol.2020.2443.
7
Comparing efficacy of reduced-fluence and standard-fluence photodynamic therapy in the treatment of polypoidal choroidal vasculopathy.比较低强度与标准强度光动力疗法治疗息肉样脉络膜血管病变的疗效。
BMC Ophthalmol. 2020 Apr 15;20(1):150. doi: 10.1186/s12886-020-01419-8.
8
Utility of a public-available artificial intelligence in diagnosis of polypoidal choroidal vasculopathy.一种公共可用的人工智能在诊断息肉样脉络膜血管病变中的效用。
Graefes Arch Clin Exp Ophthalmol. 2020 Jan;258(1):17-21. doi: 10.1007/s00417-019-04493-x. Epub 2019 Nov 4.
9
EVEREST study report 4: Fluorescein angiography features predictive of polypoidal choroidal vasculopathy.EVEREST 研究报告 4:荧光素血管造影特征预测息肉样脉络膜血管病变。
Clin Exp Ophthalmol. 2019 Jul;47(5):614-620. doi: 10.1111/ceo.13464. Epub 2019 Feb 10.
10
One-year real-world outcomes of ranibizumab 0.5 mg treatment in Taiwanese patients with polypoidal choroidal vasculopathy: a subgroup analysis of the REAL study.雷珠单抗0.5毫克治疗台湾息肉状脉络膜血管病变患者的一年真实世界转归:REAL研究的亚组分析
Int J Ophthalmol. 2018 Nov 18;11(11):1802-1808. doi: 10.18240/ijo.2018.11.11. eCollection 2018.
珠穆朗玛峰研究报告2:息肉状脉络膜血管病变随机对照试验的成像与分级方案及基线特征
Br J Ophthalmol. 2015 May;99(5):624-8. doi: 10.1136/bjophthalmol-2014-305674. Epub 2015 Mar 10.
4
A novel classification of the vascular patterns of polypoidal choroidal vasculopathy and its relation to clinical outcomes.一种新的息肉样脉络膜血管病变血管模式分类及其与临床结局的关系。
Br J Ophthalmol. 2014 Nov;98(11):1528-33. doi: 10.1136/bjophthalmol-2014-305059. Epub 2014 Jul 4.
5
One-year results of intravitreal ranibizumab combined with reduced-fluence photodynamic therapy for polypoidal choroidal vasculopathy.玻璃体内注射雷珠单抗联合低能量光动力疗法治疗息肉状脉络膜血管病变的一年结果
Clin Ophthalmol. 2014 Jan 28;8:235-41. doi: 10.2147/OPTH.S54578. eCollection 2014.
6
LAPTOP study: a 24-month trial of verteporfin versus ranibizumab for polypoidal choroidal vasculopathy.笔记本电脑研究:维替泊芬与雷珠单抗治疗息肉状脉络膜血管病变的24个月试验。
Ophthalmology. 2014 May;121(5):1151-2. doi: 10.1016/j.ophtha.2013.12.037. Epub 2014 Jan 29.
7
Comparison of the effect of reduced-fluence photodynamic therapy with intravitreal bevacizumab and standard-fluence alone for polypoidal choroidal vasculopathy.比较低强度光动力疗法联合玻璃体内注射贝伐单抗与单纯标准强度光动力疗法治疗息肉样脉络膜血管病变的疗效。
J Chin Med Assoc. 2014 Feb;77(2):101-7. doi: 10.1016/j.jcma.2013.10.012. Epub 2013 Dec 12.
8
Polypoidal choroidal vasculopathy: clinical features and genetic predisposition.息肉样脉络膜血管病变:临床特征和遗传易感性。
Ophthalmologica. 2014;231(2):59-74. doi: 10.1159/000355488. Epub 2013 Nov 21.
9
Polypoidal choroidal vasculopathy in Caucasian patients with presumed neovascular age-related macular degeneration and poor ranibizumab response.白种人年龄相关性黄斑变性伴新生血管和雷珠单抗治疗反应不佳患者的息肉样脉络膜血管病变。
Br J Ophthalmol. 2014 Feb;98(2):188-94. doi: 10.1136/bjophthalmol-2013-303444. Epub 2013 Nov 18.
10
Polypoidal choroidal vasculopathy exudation and hemorrhage: results of monthly ranibizumab therapy at one year.息肉样脉络膜血管病变渗出和出血:一年中每月接受雷珠单抗治疗的结果。
Ophthalmologica. 2014;231(2):94-102. doi: 10.1159/000354072. Epub 2013 Oct 15.